Showing results (231-240 of 244) with videos related to
Sort By:
Pageof 25
The Oncologist|April 17, 2020
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.JTO Clinical and Research Reports|April 10, 2023
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)Satoru Miura, Makoto Nishio, Hiroaki Akamatsu, et al.The Lancet. Healthy Longevity|September 13, 2022
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trialYoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, et al.Lung Cancer (Amsterdam, Netherlands)|November 21, 2024
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancerHiroaki Akamatsu, Yasuhiro Koh, Makoto Nishio, et al.European Journal of Cancer (Oxford, England : 1990)|September 16, 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B studyHiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, et al.International Journal of Clinical Oncology|November 5, 2025
Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 studyTakehiro Tozuka, Yoko Tsukita, Kohei Kushiro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2017
Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.Cancer Science|February 2, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With AtezolizumabAtsuto Mouri, Hiroshi Kagamu, Koji Tamada, et al.Lung Cancer (Amsterdam, Netherlands)|October 18, 2024
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-AsiaYuki Kato, Hibiki Udagawa, Shingo Matsumoto, et al.Pageof 25